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POPULAR SCIENCE SUMMARY OF THE THESIS 
This thesis contains four studies about survival and survivorship (life after cancer) in patients 
diagnosed with lymphoma in Sweden. All studies in the thesis are population-based register 
studies, i.e. patients are followed via national health registers. 
Lymphoma is a collective name for cancers that develop from cells in the lymphatic system, 
so-called lymphocytes. Lymphocytes are a type of white blood cells that are part of our 
immune system. There are at least 70 different subtypes of lymphoma where the course of the 
disease and prognosis vary greatly. Aggressive subtypes require immediate treatment but can 
be cured, while slow-growing, indolent subtypes are, in most cases, considered chronic 
diseases. Patients with disseminated indolent lymphoma can however live a long time with 
their disease and any treatment is primarily aimed at suppressing the disease and relieving 
symptoms - not to cure. The most common subtype is diffuse large B-cell lymphoma 
(DLBCL), which has an aggressive clinical course and affects about 600 people annually in 
Sweden. Since the mid-00s, the chemotherapy against DLBCL has been combined with an 
antibody treatment, which has improved the survival of the patients. 
In Study I, we examined how the number of patients living with different lymphoma 
subtypes has changed between the years 2000 and 2016, and how the number of newly 
diagnosed patients and their survival have changed during the same period. The background 
to the study is that lymphoma, despite the large variations between the subtypes, is often 
presented as one disease, and we therefore lack statistics at subtype level that are important 
for understanding the disease burden and for health care planning. 
We found that the number of patients living with lymphoma in Sweden has increased and that 
this applies to the vast majority of subtypes, both the aggressive and the indolent. The 
increase was a result of improved survival at the same time as more and more patients have 
been diagnosed. The fact that more and more people are living with a lymphoma diagnosis 
has consequences for how we plan the follow-up of the patients, especially with regard to 
patients with indolent subtypes who are followed-up at the clinic for many years. 
In Study II, we estimated life expectancy in patients diagnosed with DLBCL. We also 
compared the patients' life expectancy with the corresponding life expectancy of the Swedish 
population. In this way, we were able to calculate how many life years the patients were 
expected to lose, on average, as a result of their cancer diagnosis. 
The result was that the life expectancy increased in all patient groups between the years 2000 
and 2013. For example, 70-year-old male patients diagnosed with DLBCL in 2000 were 
expected to live, on average, another 6 years and 6 months, while patients of the same age 
diagnosed in 2013 were expected to live 10 years and 1 month, on average. In 2013, 70-year-
old men diagnosed with DLBCL were expected to lose an average of 4 years and 10 months 
of their life as a result of their cancer. Despite the positive trend, patients still lost many years 
due to their lymphoma. This was especially true for young patients with advanced disease 
(patients with several risk factors that together contribute to a worse prognosis). 
The remaining life expectancy for patients who were alive two years after their DLBCL 
diagnosis did not differ as much compared to the life expectancy of the general population. 
On average, these patients lost less than two years of their lives to the cancer, regardless of 




Figure 1: Life expectancy of patients diagnosed with DLBCL at 60, 70 and 80 years of age 
and surviving the first two years after diagnosis compared to life expectancy in the general 
population. The solid lines represent the life expectancy of the patients and the dashed lines 
represent the life expectancy of the general population. 
 
Study III aimed to study whether patients treated for DLBCL had an increased risk of having 
a heart attack after diagnosis compared to the general population. The background to the study 
is that one type of chemotherapy (doxorubicin) that is included in the standard treatment can 
cause damage to the heart and thus lead to an increased risk of e.g. heart failure and possibly 
also other heart diseases. In addition, many patients are older (about half of all patients are over 
70 years of age at diagnosis), and often have other underlying diseases which by themselves 
increase the risk of having a heart attack. 
We followed the patients for up to 10 years after diagnosis and saw that the risk of suffering a 
heart attack was 33% higher for the patients compared to a control group when taking into 
account age and sex. However, the excess risk was highest immediately after diagnosis and 
then gradually decreased. After about two years, there was no longer an increased risk for 
patients to have a heart attack compared to the control group. Another positive result was that 
DLBCL patients received treatment for their heart attack to the same extent as the control group 
and that an equal proportion of DLBCL patients and controls were alive 30 days after being 
hospitalized due to a heart attack. 
An important milestone for patients with DLBCL is to be disease-free for at least two years 
after end of treatment. In Study IV, we examined probabilities of being in different stages of 
the disease at different times for DLBCL patients who initially responded to treatment and for 
whom no further disease could be detected. We also examined how different patient- and 
lymphoma-specific factors were linked to the chance of remaining disease-free for more than 
two years. 
Patients who had several risk factors associated with a worse prognosis (e.g. old age, 
widespread disease or poor general condition) were less likely to remain disease-free for at 
least two years. However, there was no difference between men and women. 
Five years after end of treatment, 7 out of 10 patients were still disease-free, while almost 2 out 
of 10 had a relapse of their disease. One in 10 had died without having had a relapse of their 
disease (i.e. probably due to reasons other than their cancer).  
 
Figure 2: The proportion of patients with DLBCL who are 
disease-free immediately after treatment and who after 5 
years are still disease-free (green), have had a relapse 




Overall, the prognosis for patients diagnosed with DLBCL has improved during the 2000s, and 
for patients who survive the first two years, the prognosis today is very favorable. However, 
much remains to be done to further improve the prognosis for people affected by DLBCL. 
Patients who are not expected to tolerate treatment, who are unable to complete the treatment, 
who do not respond to treatment or have early relapses have a poor prognosis. The number of 
patients living with lymphoma has increased and is likely to continue to do so as survival 
improves even more. This means that more and more patients are living with their disease and 




POPULÄRVETENSKAPLIG SAMMANFATTNING  
Den här avhandlingen innehåller fyra studier som på olika sätt behandlar överlevnad och 
överlevarskap (livet efter cancer) hos patienter diagnosticerade med lymfom i Sverige. Alla 
studier i avhandlingen är populationsbaserade registerstudier, det vill säga, patienterna följs 
upp via nationella hälsoregister. 
Lymfom är ett samlingsnamn för cancerformer som utvecklas från celler i lymfsystemet, så 
kallade lymfocyter. Lymfocyter är en typ av vita blodkroppar som utgör en del av vårt 
immunsystem och som delas in i B-celler, T-celler och NK-celler. Det finns minst ett 70-tal 
olika underdiagnoser till lymfom där sjukdomsförlopp och prognos varierar stort. Aggressiva 
lymfom kräver omedelbar behandling, men går att bota, medan långsamt växande, indolenta 
lymfom, är mer att betrakta som kroniska sjukdomar i de flesta fall. Patienter med spritt 
indolent lymfom kan leva länge med sin sjukdom och eventuell behandling syftar främst till att 
trycka tillbaka sjukdomen och lindra symptom – inte till att bota. Den allra vanligaste 
underdiagnosen till lymfom är diffust storcelligt B-cellslymfom (Diffuse large B-cell 
lymphoma, DLBCL) som har ett aggressivt sjukdomsförlopp och drabbar cirka 600 personer 
årligen i Sverige. Sedan mitten på 00-talet kombineras cellgifterna mot DLBCL med en 
antikroppsbehandling vilket har förbättrat överlevnaden hos patienterna. 
I Studie I undersökte vi hur antalet patienter som lever med olika lymfomdiagnoser har 
förändrats mellan år 2000 och 2016, samt hur antalet nyinsjuknade och överlevnaden hos 
patienterna har förändrats under samma period. Bakgrunden till studien är att lymfom, trots de 
stora variationerna mellan underdiagnoserna, ofta studeras som en sjukdom, och att det därför 
har saknats denna typ av statistik på underdiagnosnivå som är viktig för att förstå 
sjukdomsbördan i samhället och för att planera vården.  
Vi fann att antalet patienter som lever med en lymfomdiagnos i Sverige har ökat kraftigt och 
att detta gäller de allra flesta lymfomdiagnoserna, både de aggressiva och de indolenta. 
Ökningen var en följd av att överlevnaden förbättrades samtidigt som allt fler insjuknade. Att 
fler och fler lever med en lymfomdiagnos har konsekvenser för hur vi planerar uppföljningen 
av patienterna, framförallt vad gäller patienter med indolenta lymfomdiagnoser som följs 
kliniskt under många år.  
I Studie II skattade vi förväntad livslängd hos patienter som diagnosticerats med DLBCL. Vi 
jämförde även patienternas förväntade livslängd med motsvarande förväntad livslängd hos den 
svenska befolkningen. På så vis kunde vi beräkna hur många levnadsår patienterna i snitt 
förväntades förlora till följd av sin cancerdiagnos.  
Resultatet var att den förväntade livslängden hos patienterna ökade i alla patientgrupper mellan 
åren 2000 och 2013. Till exempel förväntades 70-åriga manliga patienter som diagnosticerades 
med DLBCL år 2000 att i snitt leva i ytterligare 6 år och 6 månader, medan patienter i samma 
ålder diagnosticerade år 2013 förväntades leva snitt i ytterligare 10 år och 1 månad. År 2013 
förväntades 70-åriga män diagnosticerade med DLBCL förlora i snitt 4 år och 10 månader till 
följd av sin cancer. Trots den positiva trenden kunde vi konstatera att framförallt unga patienter 
med avancerad sjukdom (patienter med flera riskfaktorer som tillsammans bidrar till sämre 
prognos) fortfarande förlorar många år på grund av sin lymfomsjukdom.  
Den återstående livslängden för patienter som var vid liv två år efter sin DLBCL-diagnos 
skiljde sig inte lika mycket jämfört med den förväntade livslängden i befolkningen i stort. I 
snitt förlorade dessa patienter mindre än två år av sitt liv till cancern oavsett ålder vid diagnos, 




Figur 3: Förväntad återstående livslängd hos patienter som diagnosticerats med DLBCL vid 
60, 70 och 80 års ålder och som överlevt de två första åren efter diagnos jämfört med den 
förväntade livslängden i befolkningen i stort. De heldragna linjerna representerar patienternas 
förväntade livslängd och de streckade linjerna representerar den generella befolkningens 
förväntade livslängd. 
 
Studie III syftade till att studera om patienter som behandlas för DLBCL hade en ökad risk att 
drabbas av hjärtinfarkt efter diagnos jämfört med befolkningen i övrigt. Bakgrunden till studien 
är att en typ av cellgift som ingår i standardbehandlingen kan ge skador på hjärtat och på så sätt 
medföra en förhöjd risk för till exempel hjärtsvikt och eventuellt också andra hjärtsjukdomar. 
Dessutom är många patienter äldre (ungefär hälften av alla patienter är över 70 år vid diagnos) 
och många har andra bakomliggande sjukdomar, vilka i sig ökar risken för att drabbas av 
hjärtinfarkt.  
Vi följde patienterna i upp till 10 år efter diagnos och såg att risken att drabbas av en hjärtinfarkt 
var 33% högre för patienterna jämfört med en kontrollgrupp när hänsyn togs till ålder och kön. 
Överrisken var dock högst i anslutning till diagnos och minskade sedan successivt. Efter 
ungefär två år fanns inte längre någon ökad risk för patienterna att drabbas av hjärtinfarkt 
jämfört med kontrollgruppen. Ett annat positivt resultat var att DLBCL-patienterna fick 
behandling för sin hjärtinfarkt i samma utsträckning som kontrollgruppen, och att en lika stor 
 
 
andel av DLBCL-patienterna som i kontrollgruppen var vid liv 30 dagar efter 
sjukhusinläggning för hjärtinfarkt. 
En viktig milstolpe för patienter med DLBCL är att vara sjukdomsfri åtminstone två år efter 
avslutad behandling. I Studie IV undersökte vi sannolikheter för att befinna sig i olika 
sjukdomsstadier vid olika tidpunkter för DLBCL-patienter som initialt svarat på behandlingen 
och för vilka man inte längre kunde påvisa kvarvarande sjukdom. Vi undersökte även hur olika 
patient- och lymfomspecifika faktorer var kopplade till chansen att vara fortsatt sjukdomsfri i 
minst två år. 
Patienter som hade flera riskfaktorer som kopplats ihop med sämre prognos (t.ex. hög ålder, 
att sjukdomen är spridd eller dåligt allmäntillstånd) hade lägre sannolikhet att förbli 
sjukdomsfria i minst 2 år, däremot var det ingen skillnad mellan män och kvinnor. 
Fem år efter behandlingsslut var sju av 10 patienter fortfarande sjukdomsfria, medan nästan 
två av 10 fått återfall av sin sjukdom. En av 10 hade dött utan att först återfalla i sjukdom (det 
vill säga, troligen av andra orsaker än av sin cancer). 
 
Figur 4: Andelen patienter med DLBCL som är 
sjukdomsfria direkt efter behandling och som efter 5 år är 
fortsatt sjukdomsfria (gröna), har fått återfall (orangea) 
samt andelen som dött utan att först få återfall (gråa). 
 
 
Sammantaget kan vi konstatera att prognosen för patienter som diagnosticerats med DLBCL 
har förbättrats under 2000-talet, och för patienter som överlever de första två åren är prognosen 
idag väldigt god. Dock finns det fortfarande mycket kvar att göra för att ytterligare förbättra 
prognosen för personer som drabbas. Patienter som inte anses tåla behandling, som tvingas 
avbryta behandling, som inte svarar på behandling eller får tidiga återfall har fortsatt dålig 
prognos. Antalet patienter som lever med en lymfomdiagnos har ökat och kommer troligtvis 
fortsätta att öka i takt med att överlevnaden förbättras än mer. Detta innebär att fler och fler 








Non-Hodgkin lymphoma (NHL) is one of the top ten most common cancer types in Sweden. 
Although sometimes referred to as one disease, NHL is truly an umbrella term representing a 
heterogeneous group of diseases with varying clinical course and prognosis. The main data 
source for all four studies included in this thesis is the Swedish lymphoma register (SLR). This 
national quality register provides population-based data, detailed clinical information and the 
possibility to distinguish between different morphological subtypes of NHL. 
In Study I we provide a systematic presentation of temporal trends in absolute numbers of 
prevalent patients by NHL subtypes, linking them to trends in incidence, survival and mortality. 
Poisson regression was used to test for temporal trends. We found that an increasing incidence 
and improved survival have led to an increase in the prevalence of NHL overall and for almost 
all investigated subtypes between 2000 and 2016. This increase was most notable for diffuse 
large B-cell lymphomas (DLBCL) among aggressive subtypes and marginal zone lymphomas 
among indolent subtypes. The prevalence provides a measure of burden of disease, useful for 
health care planning and to optimize resource allocation. The prevalence also represents the 
number of survivors in the population, at risk for relapses and psychological and physiological 
side effects of their lymphoma or treatment. The increase in number of prevalent NHL patients 
underscores the need to develop and evaluate alternative follow-up schemes of lymphoma 
survivors since especially patients diagnosed with indolent lymphoma subtypes are followed 
in the clinic for many years.  
The most common subtype of NHL, DLBCL is the focus in study II-IV. In recent years, the 
addition of rituximab to the standard combination chemotherapy has improved outcomes in 
patients with DLBCL. Nevertheless, every fourth patient treated curatively is expected to 
experience progressive disease or relapse.  
Study II aimed to quantify trends and remaining loss in life expectancy due to DLBCL in a 
population-based cohort. Loss in life expectancy was predicted using flexible parametric 
models from diagnosis and among two-year survivors, by age, sex and age-adjusted 
international prognostic index (aaIPI). The number of life-years lost decreased over the study 
period 2000-2013 in all patient groups. However, especially younger patients (≤60 years) with 
aaIPI≥2 were still estimated to lose many life years in 2013. Among two-year survivors, the 
loss in life-expectancy was reduced to two years or less by the end of the study period, 
regardless of age, sex and aaIPI. By using novel measures, we illustrated the improvement of 
DLBCL survival in a population-based context and over the entire life-span.  
The standard chemotherapy for curative treatment of DLBCL contains the cardiotoxic 
anthracycline doxorubicin. An increased rate of heart failure is well documented following this 
treatment, whereas incidence and outcome of other cardiac complications, e.g. myocardial 
infarction, are less well studied.  
 
 
In Study III we assessed the incidence, characteristics and outcome of acute myocardial 
infarctions (AMI) in curatively treated patients with DLBCL. Patients were matched to 
lymphoma-free comparators and the rate of AMI was estimated using flexible parametric 
survival models incorporating repeated events. Overall, DLBCL patients had a 33% excess rate 
of AMI compared to the general population. However, the excess rate was most pronounced 
during the first year after diagnosis and diminished after 2 years. The strongest risk factors for 
AMI were advanced age, male sex and pre-existing comorbidity. There was no difference in 
AMI characteristics, extent of treatment or 30-day survival following hospitalization for AMI 
between DLBCL patients and comparators. The increased risk of AMI especially during the 
first 2 years and among elderly patients calls for improved cardiac monitoring. 
In Study IV we estimated real-world probabilities for lasting remission by clinical disease 
characteristics using a multi-state model approach. DLBCL patients who achieved remission 
after primary treatment were followed for repeated relapses and death. Flexible parametric 
models were used to model transition rates between disease stages accounting for competing 
events at each transition. At 2 years after end of primary treatment, 81% of the patients 
remained in remission, 13% had relapsed and 6 % of patients had died in first remission. The 
probability of remaining in remission for at least 2 years was reduced by 24 percentage units 
for patients with international prognostic index, IPI 4-5 compared to patients with IPI 0-1. On 
average, these patients lost 4.4 months of being in remission the first 2 years. Only 43% of 
relapsing patients achieved a second remission and half of them (51%) relapsed again - 
reflecting the difficulties in treating relapsing patients. 
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1.1 NON-HODGKIN LYMPHOMA 
Non-Hodgkin lymphoma (NHL) is one of the top ten most common cancer types in Sweden 
and responsible for approximately 4% of all new cancers[1]. In 2016, the Swedish population 
comprised a total of 22 671 NHL survivors, or prevalent NHL patients[1].  
Lymphoma develop from a type of white blood cells called lymphocytes. Lymphocytes are 
part of the immune system and include B cells, T cells and natural killer cells (NK cells). NHL 
can arise in any of these types of cells, although about 85-90 % of NHL arise from B cells.  
The term NHL originate from the traditional division into Hodgkin and non-Hodgkin 
lymphoma but is not used that often anymore as a more refined subtype classification system 
has been developed. Although sometimes still referred to as one disease, NHL is truly an 
umbrella term representing a heterogeneous group of diseases with varying clinical course and 
prognosis. A more clinically relevant division distinguishes between aggressive lymphomas 
and indolent lymphomas. 
1.1.1 Aggressive/Indolent lymphoma 
Aggressive lymphomas show an aggressive growth pattern. These tumors grow rapidly and 
often cause general symptoms in the form of fever, night sweats and weight loss (B symptoms). 
Without treatment, survival is short. Treatment is started immediately after diagnosis and can 
be curative.  
Indolent lymphomas grow slowly. Treatment is given if the disease causes symptoms or has a 
large tumor burden, however some patients can be followed without requiring treatment for 
many years. Indolent lymphomas are mostly regarded as chronic diseases and the purpose of 
the treatment is not curative but to push back the disease and prolong the time to progression. 
However, if the disease is diagnosed at an early stage, when localized to only one nodal site, 
cure may be possible with local radiotherapy. Although most patients are diagnosed with more 
widespread disease and thus cannot be treated curatively, long remissions are seen and survival 
is often long. Indolent lymphomas can transform into aggressive lymphomas. 
1.1.2 Subtype classification 
A more refined subtype classification system of NHL has been implemented based on clinical 
findings, morphology, immunophenotyping and molecular genetics[2] and the classification 
system is continually revised based on advancement in the understanding of the disease. In the 
widely established WHO classification, the term lymphoma has been replaced by mature 
lymphoid neoplasms. This group also encompasses chronic lymphocytic leukemia and multiple 






Figure 1.1: Distribution of NHL subtypes from 2000 to 2016 based on data from the Swedish 
lymphoma register 
 
1.2 DIFFUSE LARGE B-CELL LYMPHOMA 
The most common lymphoma subtype (and the main focus in three of the four studies included 
in this thesis) is diffuse large B-cell lymphoma (DLBCL)[3]. DLBCL is an aggressive type of 
lymphoma that develops from B cells.  
The term diffuse large B-cell lymphoma describes the histological picture. The cells are large, 
grow diffusely and express B-cell markers such as CD20 and CD19. The cell-of-origin is a B 
cell from the germinal center (GCB-DLBCL) in the secondary lymph follicles or a cell that has 
passed the germinal center and has just begun its development towards plasma cell 
differentiation, a so-called activated B cell (ABC-DLBCL)[4]. 





































In the latest WHO classification of tumors in lymphatic and hematopoietic tissue, from 2016, 
DLBCL is in turn further divided into several subgroups[2]. The most common is the 
unspecified group (DLBCL without further specification, UNS). In addition, several groups 
are distinguished based on, among other things, localization (mediastinum, CNS) and histology 
(T-cell-rich, ALK-positive, etc.). 
1.2.1 Presentation 
The first sign of illness is typically a rapidly growing mass, often in lymph nodes but it can 
arise in any organ, sometimes in combination with the so-called B symptoms; night sweat, 
weight loss and fever.  
1.2.2 Risk factors 
The incidence of DLBCL increases with age, median age at diagnosis is 70 years and it is more 
common in men than women. Risk factors for DLBCL include; immune suppression as in 
HIV/AIDS or following solid organ transplantation, autoimmune diseases (e.g. Sjögrens 
syndrome, systemic lupus erythematosus, rheumatoid arthritis etc.), Hepatitis C virus 
seropositivity, a family history of lymphoma and a high BMI[5-8]. 
1.2.3 International Prognostic Index, IPI  
A prognostic scoring system called “International Prognostic Index” or IPI is used in clinical 
practice to determine risk categories and prognosis[9]. The score is calculated by summing risk 
factors where one point is given for each of the following:  
• age >60 years 
• elevated lactate dehydrogenase in serum (S-LDH)  
• WHO/ECOG performance status >1 
• Ann Arbor stage III-IV 
• involvement of two or more extranodal sites.  
A simplified score called the age-adjusted IPI (aaIPI) can be used to compare patients within 
age categories[9]. One point is then given for each of the following:  
• Ann Arbor stage III-IV 
• elevated S-LDH  
• WHO/ECOG performance status >1.  
Since the development of IPI back in 1993, several other prognostic scores have been suggested 
with the goal to further improve risk stratification, e.g., NCCN-IPI[10], R-IPI[11], DLBCL-
PI[12]. However, IPI has been shown to remain a valid prognostic score[13, 14] and age-




According to the Swedish clinical guidelines[15], the standard treatment for patients diagnosed 
with DLBCL is 6 cycles (given with a 14- or 21- day interval) of the combination of 
cyclophosphamide, doxorubicin, vincristine and prednisone together with the anti-CD20 
monoclonal antibody rituximab (R-CHOP). For younger patients (≤65 years) with aaIPI = 2-3, 
etoposide may be added to R-CHOP (R-CHOEP). The antibody rituximab targets the CD20 
cell surface protein, present on most B-cell malignancies. 
A reduced R-CHOP treatment called R-miniCHOP is increasingly used in very old patients 
(guideline > 80 years). The dose of doxorubicin and cyclophosphamide in R-miniCHOP has 
been halved while the doses of rituximab, vincristine and prednisone are unchanged.  
For patients with impaired cardiac function, doxorubicin can either be replaced by etoposide 
(R-CEOP) or alternatively, the infusion time for doxorubicin can be prolonged. 
1.2.5 Changes in treatment praxis during the study period (2000-2016) 
The most significant change in the treatment guidelines during the study period was the 
addition of the antibody rituximab to the standard treatment. Rituximab was approved by the 
US Food and Drug Administration in 1997[16] and was gradually introduced in Sweden within 
clinical trials in the beginning of the 21st century. Rituximab was adopted in the national 
treatment guidelines as standard treatment for all DLBCL patients regardless of aaIPI in 2006.  
The national guidelines are continuously updated as new evidence of treatment efficacy 
becomes available and other, minor, changes have been made over the years regarding, e.g., 
number of recommended treatment cycles, or the indications for administration of CNS-
prophylaxis. 
1.2.6 Follow-up guidelines 
Patients in complete remission (CR) after completion of treatment are followed with regular 
visits to the clinic during two years (in general every three months during the first year and 
every 6 months during the second year but with large local variation). The purpose of the visits 
is to control for potential relapse, control and treat potential late effects, provide psychosocial 
support and evaluate needs of sick-leave and rehabilitation etc. The recommended follow-up 
has been shortened from previously five years to the current two years due to the reduced 
relapse risk after two years. 
1.2.7 Relapsed/refractory disease 
Approximately 20-30% of curatively treated patients are either refractory to first line treatment 
or relapse within 5 years[17]. 
Curative treatment for younger and fit relapsing patients (age ≤70 years, performance status 
and comorbidity load are also considered) include high-dose chemotherapy and autologous 
stem cell transplant (ASCT). Eligible patients are started on second-line chemotherapy (GDP, 
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DHAP, ICE with or without rituximab) and patients demonstrating chemosensitive disease are 
considered for high-dose chemotherapy after 3-4 cycles. Younger patients <65-70 years with 
recurrence after high-dose treatment can also occasionally be considered for allogeneic stem 
cell transplantation.  
Many patients are however not eligible for ASCT, mainly due to high age. Among these, fit 
patients are recommended R-GEMOX, R-Bendamustine or R-IME or the possibility of 
inclusion in a clinical trial. Non-curative intent treatment, with the purpose of relieving 
symptoms include radiotherapy or low-toxic chemotherapy e.g. cyclophosphamide, 
trophosphamide or steroids. 







2 LITERATURE REVIEW 
The following literature review contains three sections and examines the current literature 
related to the studies in this thesis. The first section reviews the literature on recent trends in 
prevalence, incidence, mortality and survival of NHL and its subtypes in populations similar 
to the Swedish population (Study I). The following two sections focus on survival and 
survivorship following a diagnosis of DLBCL. First, by reviewing the literature regarding long-
term survival after DLBCL, especially following the introduction of rituximab (Study II & IV). 
Secondly, by reviewing the literature on cardiovascular morbidity and risk of myocardial 
infarction among patients treated for DLBCL (Study III). 
2.1 RECENT TRENDS IN PREVALENCE, INCIDENCE, MORTALITY AND 
SURVIVAL OF NHL AND ITS SUBTYPES 
While there are several examples of studies on trends in incidence, survival and mortality of 
NHL, the knowledge about prevalence trends is sparse. However, the number of prevalent 
patients in the population will depend both on the number of newly diagnosed patients 
(incidence) and the survival of those patients (survival and mortality). It is therefore natural to 
review the literature regarding those metrics in order to indirectly capture what is known about 
the trends in prevalence of NHL.   
2.1.1 Incidence trends  
The number of newly diagnosed patients with NHL in Sweden has grown dramatically since 
the 1960s but after decades of a steeply increasing incidence of NHL, the increase started to 
level off in the 1990s[18]. Similar shifts in incidence trends have been seen in most high-
income countries[18-22]. Notably, the incidence has continued to increase in some countries, 
although the level of increase is markedly lower than a few decades ago[23, 24], while it has 
stabilized[21, 22] or even started to decline in others[25]. 
Less is known about the incidence trends of the NHL-subtypes; however, a few studies exist 
that have systematically estimated subtype-specific trends. Despite the attenuation of the 
incidence of NHL overall, the incidence of several subtypes of NHL have been reported to 
increase in more recent years, including Burkitt lymphoma[3, 21, 26], marginal zone 
lymphoma[3, 21] and mantle cell lymphoma[3, 21, 27]. A pronounced increase in incidence of 
mantle cell lymphoma has been noted among white males over 70-75 years of age[21, 27]. On 
the other hand, the incidence of small lymphocytic lymphoma (SLL)/chronic lymphocytic 
lymphoma (CLL) has been reported to plateau or even decline[3, 21, 22]. 
Not all subtypes show consistent incidence trends across populations. For the most common 
subtype, DLBCL, the incidence trends are somewhat divergent. For instance, during the past 
15-20 years, the incidence rates of DLBCL increased in Australia[21] and Canada[22], 
remained stable in the Netherlands[26], while starting to decrease in the US[25]. In a Swedish 
study from 2014, estimated DLBCL trends 2000-2010 where stable among women but there 
was a yearly increase in incidence among men[28]. As for follicular lymphoma (FL), a stable 
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incidence trend was seen in Sweden 2003-2007 which is in line with data in a Canadian study 
from 2017 where there was no statistical change in incidence of FL in either sex between 2003 
and 2013[22]. In contrast, FL incidence increased prior to 2007 in the US and Australia[21, 
25]. In the US, FL incidence rates have started to decline after 2007[25]. 
Diagnosis and classification of NHL is not always straightforward and despite the detailed 
categorization developed by WHO, there are non-negligible numbers of lymphoid 
malignancies recorded in the registers as unclassified, possibly due limited diagnostic material, 
or patients unfit for further diagnostic work-up. Several studies have, however, reported that 
this number is decreasing[3, 21, 24]. The unclassified lymphomas are a heterogeneous group 
that is difficult to study and the subtype to which these cases truly belong will be 
underestimated.  
2.1.2 Mortality trends  
Up to the mid/late 1990s, there was a steady increase in NHL-related mortality, but from the 
beginning of the 21st century, the mortality started to decline. This pattern has been observed 
in most high-income countries[19, 20, 24, 25].  
It is not directly possible to decompose mortality rates into trends for NHL subtypes because 
death certificates often do not record subtypes. However, in a US SEER study, deaths were 
linked to incident cases for calculation of so-called incidence-based mortality rates (IBM) in 
order to estimate subtype-specific mortality trends[25]. Follicular lymphoma IBM was flat 
during 1990-1997 and then declined steeply, while the mortality observed for DLBCL and 
CLL/SLL peaked in 1995-1998 and then declined.  
2.1.3 Survival trends  
Survival after NHL has improved over the past decades[20, 29], although the extent of the 
improvement varies by sex, age and lymphoma subtype[22]. The improvement has been 
especially dramatic for patients diagnosed with B-cell lymphomas[3, 25, 26, 28-30]. The 
improved survival follows treatment advancements over the past decades that include 
introduction of new chemotherapy drugs and monoclonal antibodies (rituximab), autologous 
stem cell transplantation and optimized radiation therapy to reduce toxicity. 
2.1.4 Prevalence 
The data on prevalence at the subtype level is meager. In a study from 2014, the prevalence of 
different lymphoma subtypes in the UK were presented[31].The authors concluded that the 
prevalence estimates tend to be higher for men than women across all main subtypes, largely 
due to underlying differences in incidence patterns while there was no difference in survival 
between the sexes. However, this study did not investigate temporal trends.  
Overall, the reported incidence, mortality and survival trends combined point to an increasing 
prevalence of NHL in the population. Although the steep increase in incidence of NHL overall 
observed in Scandinavia prior to the 1990s has leveled off, more recent studies have 
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demonstrated increasing incidences in specific subtypes of NHL and as new treatment options 
have become available during the past few decades, survival has improved dramatically.  
While the increasing incidence, decreasing mortality and improving survival imply increasing 
prevalence, no systematic review on prevalence trends at the subtype level has been performed. 
As trends vary between populations it is not clear how the trends reported in other high-income 
countries can be generalized to the Swedish population nor how these trends translate into 
actual numbers of prevalent patients. 
2.2 DLBCL SURVIVAL FOLLOWING THE INTRODUCTION OF RITUXIMAB 
As stated in the previous section, survival in patients with B-cell lymphomas has improved 
dramatically during the past 1-2 decades following the addition of the anti-CD20 antibody 
rituximab to standard chemotherapy. As first shown in clinical trials, the addition of rituximab 
to CHOP-like chemotherapy improved the outcome of all subgroups of DLBCL patients, 




Figure 2.1: Event-free Survival among 399 Patients Assigned to Chemotherapy with 
Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) or with CHOP plus 
Rituximab. Reproduced with permission from New England Journal of Medicine Coiffier et al 




Observations from controlled trials with selected patients have further been generalized to “real 
world patient groups” composed of a wide mixture of patients, including many who would not 
be eligible for participation in randomized clinical trials[35-37].  
The addition of rituximab has prolonged survival due to a lower rate of disease progression 
during therapy and fewer relapses among patients in complete remission[32, 33, 38, 39] yet 
20-30% are still either primary progressive or relapse within a few years from diagnosis[17, 
36, 40]. 
The majority of relapses occur early but there is a pattern of continuous relapse risk[35, 36, 38, 
40, 41] and 5-8% of patients achieving CR on primary treatment relapse after more than 5 
years[39, 42, 43]. The survival after relapse is poor[40, 44-49] although late occurring relapses 
seem to have slightly better prognosis[39, 43, 50]. 
At least two studies exist that have compared DLBCL survival to that of the general population. 
In a study by Maurer et al, patients achieving 24 months of event-free survival had a subsequent 
survival comparable to that of the general population matched on age and sex[36]. In a study 
by Jakobsen et al, survival of patients with DLBCL responding to immunochemotherapy with 
complete remission, was compared to an age-and sex matched general population[35]. This 
study confirmed the favorable outcome shown by Maurer et al although the survival was 
slightly reduced relative the general population despite many years in complete remission. 
However, patients younger than 50 years at diagnosis had a survival comparable to that of the 
general population. Maurer and Jakobsen both stress the importance of avoiding relapse since 
the excess mortality after 24 months was mainly driven by relapses. 
In conclusion, rituximab has substantially improved the survival after DLBCL and patients 
who successfully respond to primary treatment and have no adverse events during the first 2 
years thereafter seem to have only a slightly reduced survival compared to the general 
population. However, despite advancements in the primary treatment, many patients still 
experience relapses and even after years in remission the persistent risk of relapse may prevent 
a normalization of survival. Therefore, quantifying the potential loss in life expectancy in a 
population-based setting (study II) as well as describing how patients move through different 
states (relapse, second remission, death etc.) following their disease (study IV) can provide new 
insight in long-term survival and survivorship after DLBCL. 
2.3 CARDIOVASCULAR MORBIDITY AND RISK OF MYOCARDIAL 
INFARCTION IN PATIENTS TREATED FOR DLBCL  
The anthracycline doxorubicin (abbreviated with an H in R-CHOP, as it was initially described 
as hydroxydaunorubicin) is known to be cardio-toxic and increases the risk of later 
cardiomyopathy and heart failure (CHF), and possibly also of cardiovascular diseases (CVD) 
such as AMI[51-54]. 
According to clinical guidelines, doxorubicin should be avoided in patients with severe cardiac 
comorbidity and low left ventricular ejection fraction at primary lymphoma diagnosis, and 
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modified chemotherapy regimens should be used. However, many patients are older and/or 
have milder comorbidity at diagnosis, such as hypertension or diabetes, which could also have 
implications for risk of adverse cardiac events[55]. 
Chemotherapy-associated CHF has been well described[53, 56-61] and the risk of doxorubicin-
induced CHF has been shown to be dose dependent, i.e. the risk increases with increased life 
time cumulative dose[53, 60, 61]. Nevertheless, low to moderate doses of anthracycline-based 
chemotherapy have been associated with early development of subclinical abnormalities of 
cardiac and vascular function that in other populations are associated with future occurrence of 
a range of cardiovascular events[52, 62]. 
In a study based on SEER-data, DLBCL patients older than 65 years at diagnosis were 
compared to cancer-free controls. DLBCL patients were found to have a significantly increased 
risk of AMI, especially during the first 6 months after diagnosis[63]. The relative risk of AMI 
was higher for patients without prior CVD (when compared to controls without prior CVD) 
than the relative risk of AMI among patients with prior CVD (when compared to controls with 
CVD). The authors claim that this unintuitive finding can be explained by the fact that patients 
without a history of CVD receive more doxorubicin than patients with a history of CVD. 
However, even if the relative risks are reported higher for patients without CVD compared to 
the controls[63], the absolute risk of AMI is probably higher among patients with history of 
CVD than among patients without prior CVD.  
Patients with a pre-existing CVD may receive fewer cycles and/or lower doses of 
chemotherapy and are less likely to be treated with doxorubicin[53, 59, 63]. Lowering the dose 
of doxorubicin in patients with cardiovascular disease reduces risk of secondary cardiovascular 
events but also increases the risk of death, presumably due to an increase in risk of disease 
progression[63]. 
Whether or not a patient should be disqualified for potentially life-saving treatment due to 
baseline CVD is a difficult but important question since many DLBCL patients are older and 




3 RESEARCH AIMS 
The overall aims of this thesis were to: 
• Advance the understanding of the NHL disease burden by describing recent trends in 
the prevalence (i.e. the number of survivors in the population) of NHL subtypes and 
correlate those to trends in incidence, survival and mortality.  
 
• Quantify loss in life-expectancy following a diagnosis of DLBCL in a population-based 
setting. 
 
• Describe the excess risk and timing of myocardial infarction in patients treated 
curatively for DLBCL (when contrasted to a DLBCL-free comparison group). 
 
• Describe patient trajectories following DLBCL using multistate models with emphasis 




4 MATERIALS AND METHODS 
All studies included in this thesis are population-based register studies. 
4.1 DATA SOURCES 
4.1.1 The Swedish Lymphoma Register 
The main data source in the four studies included in this thesis is the Swedish Lymphoma 
Register (SLR). Due to the heterogeneity of the lymphoma diagnoses and their 
subclassification, SLR is essential for follow-up of patients in subgroups that can otherwise not 
be distinguished in the National Cancer Register. 
SLR was initiated in 2000 on behalf of the Swedish Lymphoma Group with the purpose to 
optimize the care of patients with malignant lymphomas. Chronic lymphocytic leukemia (CLL, 
which belongs to the same group of mature lymphoid malignancies) has a separate quality 
register since 2007 and hence this diagnosis is not included in SLR.  
The SLR includes all incident lymphomas diagnosed in patients aged 18 years and above. Pure 
autopsy findings are not included. SLR includes detailed level information of lymphoma 
subtype (the register contains 78 subtypes, unspecified lymphomas included). From 2007 the 
register collects data on first line treatment and response to treatment, and from 2010 
information on relapse is also collected. Compared to the National Cancer Register to which 
reporting is mandatory by law, the coverage is around 95%[64]. There is however a lag in the 
registration, where the median time from diagnosis to registration is about 6 months (80% are 
registered within 14 months from diagnosis)[64]. 
During 2017-2019 we initiated an extensive nationwide data collection and update of the SLR 
(Figure 4.1). In phase one, approximately 5000 patients diagnosed with DLBCL between 2007 
and 2014 were identified in SLR and medical charts for 98% were localized and reviewed by 
trained research nurses. The purpose was to ensure the completeness of the information 
regarding treatment, response to treatment and relapse information.  
4.1.2 Data collection 
In addition to the update of SLR, in phase two, data including information on later line 
treatment and clinical presentation at relapse, were collected for relapsing patients and patients 
not responding to first line treatment. After the first chart review, a total of 822 patients were 
found to meet these criteria.  
When the data collection ended in 2019, the final cohort with relapse or progressive or stable 
disease (PD/SD) as best response to first-line treatment encompassed 761 (92.6%) patients. 
Live patients had been asked to give their informed consent to have their data collected, 15 
patients (1.8%) declined to participate and were therefor not included, and in addition 46 
patients (5.5%) never had their data collected due to administrative reasons (e.g. that the 
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patients had moved between different hospitals which made it difficult to localize the full 





Figure 4.1: Schematic overview of the data collection. 
 
4.1.3 SWEDEHEART 
In the third study in this thesis, SLR was linked to the Swedish national quality register 
SWEDEHEART. SWEDEHEART started in 2009 by the merge of four already existing 
quality registers (RIKS-HIA, SEPHIA, SCAAR, and the Swedish Cardiac Surgery Registry) - 
forming Sweden's largest quality register. Patients eligible for registration in SWEDEHEART 
receive written information about the register, their voluntary participation and about the 
possibility to decline participation[65]. 
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We mainly use data from RIKS-HIA, this register includes all patients who are treated in 
coronary care units or other specialized facilities due to acute coronary syndrome/myocardial 
infarction. The register includes detailed information on clinical characteristics, symptoms, 
diagnoses and medications during hospitalization and at discharge. When the RIKS-HIA 
register started in 1991, 19 hospitals participated but today the register is nationwide and 
includes all Swedish hospitals treating acute cardiac diseases. The register has a 95-96% 




Figure 4.2: SWEDEHEART is a merger of four quality register: RIKS-HIA, SEPHIA, SCAAR 
and Swedish Cardiac Surgery Register 
 
4.1.4 Additional data sources 
SLR is regularly linked to the Swedish Cause of Death Register to retrieve information on dates 
of death (if applicable). In addition, the data was further linked by the use of personal 
numbers[66] to: The National in- and outpatient registers, the National Cancer Register and the 
Prescribed Drug Register.  
Population life tables stratified on age, sex and calendar year obtained from the Human 
Mortality Database project (HMD) were used in study II. HMD receives raw data from 
Statistics Sweden and convert it to life-tables according to a common methods protocol[67]. 
The life-tables are available for public use at http://mortality.org. 
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4.2 ETHICAL CONSIDERATIONS 
The studies included in this thesis are all observational register-based studies. This means that 
there are no interventions done to the patients (as compared to in clinical trials) and therefore 
no risk of directly harming the patients involved. However, we are handling personal- and 
highly sensitive information about the patients included in the studies. Therefore, ethical 
considerations in register-based studies naturally revolves around how researchers handle this 
data and how we make sure that the public’s confidence in research is preserved. It is crucial 
that: 
• We handle the data in a secure way to protect the patients’ privacy and security. This 
means that access to data is limited to researchers directly involved in data analysis, 
that data is stored in a secure way (on encrypted servers set up for this purpose) and 
that it is at least pseudoanonymized (e.g. by the use of random identification number 
instead of personal number and that we limit the number of variables as much as 
possible to obstruct indirect identification). 
• We as researchers secure the quality of the data so that it can be used to pursue valid 
and important research, for the group under study and the society.  
• We choose appropriate methodology, design and statistical methods for the research 
question at hand.  
Processing of sensitive personal data without explicit consent is prohibited, according to the 
general Data Protection Regulation (GDPR), but there are a number of exceptions, for example 
research with approval from the Ethical Review Board before the research begins. When 
informed consent is not required from the participants, we need to bear in mind that most people 
are probably not even aware of their data being used, and while it seems an impossible task to 
keep track of the numerous studies that are pursued based on these data, we need to ensure that 
we facilitate such work by e.g., reporting new data linkages to the data protection officer.  
One could also argue that the research conducted is not always beneficial for the individuals 
included (but can potentially be beneficial for future patients). On the other hand, the general 
inclusion is an important aspect that allow for true population-based research that makes the 
results applicable also to patient-groups that are normally not included in e.g., randomized 
clinical trials.  
4.3 METHODOLOGICAL CONSIDERATIONS 
4.3.1 Study I 
4.3.1.1 Different measures capture different aspects of disease burden 
Incidence, survival, mortality and prevalence are all measures that are important indicators of 
disease burden and that form the basis for cancer control activities[68]. The different measures 
capture different aspects of a dynamic, time-dependent process. Hence it is important to explore 
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Figure 4.3: The “Epidemiologist’s bathtub” shows the relationship between Incidence, 
mortality, survival and prevalence. The incidence is represented by the water entering the tub 
from the tap, the mortality is represented by the water leaving the tub through the drain, the 
survival time is the time the water stays in the tub and the prevalence is represented by the 
amount of water that is in the tub at any given moment. 
 
4.3.1.2 Incidence 
Trends in incidence may be explained by changes in the distribution of risk factors (disease 
ethology), clinical work-up leading up to the diagnosis and/or the cancer registration process 
itself. Because age is such a strong risk factor for cancer, incidence rates are often age-
standardized to facilitate comparison between groups or over time. This can be done directly 
or indirectly, either by applying the age-distribution of a standard population (e.g. the World 
Standard Population) or by applying the age-distribution from one of the groups under 
comparison. In this study, incidence and mortality rates were age standardized using the age-
distribution in Sweden in 2000 as the standard population.  
4.3.1.3 Prevalence 
Prevalence can be defined as the number of persons alive at a given time point who have had 
a cancer diagnosis (ever) or expressed as the number of persons alive that have been diagnosed 
with cancer in a certain time-window e.g. in the previous five years. Different time windows 
may capture different aspects of the disease burden. A short time window may reflect the 
number of patients in the population with an active disease undergoing treatment while a wider 
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time window may capture a larger number of patients in remission that may experience late 
effects of their cancer. The prevalence in a specified time window also reflects the number of 
patients that are actively monitored in health care. 
We defined the prevalence as the number of patients alive December 31st each year and who 
had a recorded diagnosis of NHL in the previous 2, 5 or 10 years. The different time-windows 
were chosen to reflect both varying clinical course by subtype, and differences in the 
recommended duration of active patient monitoring in clinical practice over time[71-75].  
4.3.1.4 Survival 
Survival refers to the proportion of patients diagnosed with the cancer under study who are still 
alive at various points in time after diagnosis. Often when we want to measure the survival 
after cancer, we are interested in deaths associated with the diagnosis of cancer itself. However, 
cancer patients may die from a number of causes, sometimes completely unrelated to their 
cancer diagnosis. These deaths are known as competing events, meaning that they effectively 
prevent all other events from eventually occurring. Since we can only die once, having died 
from another cause means you are no longer at risk to die from cancer. 
When estimating cancer survival, we therefore have two options: we can either eliminate deaths 
due to other causes, i.e. ignore them and estimate a quantity called net survival that assumes 
that competing events did not happen, or accommodate them and estimate the cancer survival 
in the presence of the competing events (sometimes called crude survival).  The choice between 
the two approaches depends on the research question and intended target audience. 
4.3.1.5 Net survival or net probability of death 
We can estimate net probability of cancer death by censoring the survival time when a 
competing event occurs (e.g. at death from another cause based on information from death 
certificates). The strict interpretation of net probability of death due to cancer is: the probability 
of death in a hypothetical world where cancer is the only possible cause of death. This can 
sound a bit awkward, however, eliminating any background mortality makes comparisons 
across groups of patients more meaningful in many epidemiological investigations (e.g. across 
age-groups or between countries). 
Lymphoma subtypes are not specified on death certificates so in order to capture subtype-
specific deaths we can instead contrast the number of deaths (all-cause) in our patient 
population to the number of deaths that we would expect if the cancer patients did not have 
cancer. This is known as excess mortality and is defined as: 
𝐸𝑥𝑐𝑒𝑠𝑠 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 = 𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 − 𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 
The survival analogue to excess mortality is relative survival and is defined as: 






The advantage of this approach is that information on cause of death is not required. Another 
advantage is that excess mortality captures all deaths, both directly and indirectly due to the 
cancer (e.g. including also treatment related side effects)[76]. 
Expected mortality is often taken from population life tables stratified by age, sex and calendar 
year (see section 4.1.4). In theory, the expected mortality would be from a population 
completely free from the cancer under study but in reality, we use population life tables that 
contain deaths due to the cancer under study. It has been shown that this introduced bias in 
practice is so small that it does not affect the estimated survival proportions of cancer forms as 
rare as lymphoma[77]. 
When estimating excess mortality, we make the following assumption: 
• exchangeability i.e. that the only difference between the cancer patients and the general 
population is the fact that the cancer patients were diagnosed with cancer and that the 
potential difference in mortality is directly or indirectly due to the cancer. 
 
• Independence i.e. that the time to death from the cancer in question is conditionally 
independent of the time to death from other causes. i.e. there should be no factors that 
influence both the cancer and non-cancer mortality other than those controlled for in 
the estimation.  
Unfortunately, we cannot test the validity of this assumption in a given data set but must rely 





Table 4.1: Different population measures of cancer burden, their interpretation and factors 
affecting them. 
Measure Interpretation Affected by: 
Incidence Number of newly diagnosed patients per 
person-years at risk in the population 
Risk factors (disease etiology), 
diagnostic routines, cancer 
registration process 
Mortality  Number of deaths per person-years at 
risk in the population 
Incidence, survival 
Prevalence Number of live patients at a specific time 
point 
Incidence, survival  
Survival  Proportion alive among the patients 
(Often reported as net survival or overall 
survival) 
Treatment, prognostic factors 
(age, comorbidity etc), care, 
incidence (e.g. if more cases are 
detected early due to screening 
this will affect survival) 
 
4.3.1.6 Estimating trends 
Poisson regression models (adjusted for age at diagnosis and sex) were used to test for trends 
in incidence, excess mortality and prevalence by assuming a linear effect of calendar year on 
each outcome. The Poisson regression model is commonly used to model counts or event rates 
i.e. number of deaths or number of new cases (incidence) per 100 000 person-years. These 
models estimate rate ratios with 95% confidence intervals, which can be interpreted as the 
average annual effect on the incidence or mortality.  
Interactions between calendar year and age at diagnosis (≤70/>70 years) and sex were included 
to test for effect modification. A sandwich estimator[78] of the standard errors was used in the 
prevalence models to account for non-independent observations since the same patient may 
attribute to the prevalence many years in a row.   
This framework also enables a straightforward and commonly used extension of the Poisson 
regression model (via a user defined link function) to allow for modelling of excess mortality 




4.3.2 Study II 
4.3.2.1 Estimating loss in life expectancy 
Survival is commonly expressed as a summary measure at arbitrary time points e.g. proportion 
of patients alive at five years after diagnosis. In this study, we instead estimate the loss in life 
expectancy (LEL) a clinically relevant and easy-to-interpret measure of survival of the patient 
that summarizes the prognosis over the entire life-span. 
The LEL provides a useful summary measure for how close (within how many years) the life 
expectancy for the patients is predicted in comparison to that in the general population. The 
loss in expectation of life is of specific interest in young patients (potential life years that can 
be lost is higher compared to chronologically older patients). 
The LEL is defined as the difference between the life expectancy (mean all-cause survival) in 
the cancer population and that in the general population (matched on age, sex and year). Since 
we seldomly have follow-up data until all patients are dead (i.e. when the survival function 
reaches zero), estimation of life expectancy generally requires extrapolation of the survival 
function beyond the available data. Hakama and Hakulinen[80] suggested extrapolation of the 
relative survival and to use the relationship between relative survival, observed and expected 
survival to obtain the all-cause survival function rather than extrapolating the all-cause survival 
function directly. The all-cause survival function may extrapolate poorly but the excess 
mortality is typically low at the time of follow-up where extrapolation is used (i.e. several years 
after the cancer diagnosis). 
 
Figure 4.4: The loss in life-expectancy is defined as the difference between the mean all-




We used methods developed by Andersson et al[81] where the cumulative excess mortality is 
extrapolated by using a flexible parametric survival model. When evaluated against historical 
data, the extrapolated relative survival gave a good estimate of the mean survival time in most 
age groups and for most cancer sites[81]. 
4.3.2.2 The flexible parametric survival model 
The flexible parametric survival models (FPM) were first introduced by Royston and 
Parmar[82]. In contrast to the widely used Cox model, FPM explicitly estimates the baseline 
hazard function. In a Cox model, no parametric shape of the baseline hazard needs to be 
assumed. However, using parametric models have several advantages when it comes to 
prediction, quantifications (e.g. absolute and relative differences in risk) and modelling time-
dependent effects or on multiple time scales. The flexible parametric model has also been 
extended to a relative survival framework and can be used to estimate excess hazards (relative 
survival)[83, 84]. 
The baseline hazard function is estimated in FPM by using restricted cubic splines. The 
baseline rate is modelled on the log cumulative hazard scale (or the log cumulative excess 
hazard scale if we are using relative survival). 
𝑙𝑛[𝐻(𝑡|𝒙𝑖)] = 𝑙𝑛[𝐻0(𝑡)] + 𝒙𝑖𝜷 
Restricted cubic splines are restricted to be linear before first knot and after last knot. For 
knots,𝑘1, ⋯ , 𝑘𝑘 a restricted cubic spline function can be written: 
𝑠(𝑥) = 𝛾0 + 𝛾1𝑧1 + 𝛾2𝑧2 + ⋯ + 𝛾𝑘−1𝑧𝑘−1  
For example, with a flexible parametric model using 4 knots to model the baseline hazard we 
can write: 
𝑙𝑛[𝐻(𝑡|𝑥𝑖)] = 𝜂 𝑖 = 𝛾0 + 𝛾1𝑧1 + 𝛾2𝑧2 + 𝛾3𝑧3 + 𝑥𝑖𝛽 
Where 𝛾0 + 𝛾1𝑧1 + 𝛾2𝑧2 + 𝛾3𝑧3 is the log baseline cumulative hazard and 𝑥𝑖𝛽 is the log 
hazard ratio. This is a proportional hazards model and the estimates that we obtain from the 
flexible parametric survival models are similar to those obtained from a standard Cox model if 
a sufficiently large number of degrees-of-freedom is used to model the spline function. 
4.3.2.3 Sensitivity analysis 
Although flexible parametric models are parametric “by nature”, the use of splines to model 
the baseline has previously been shown to allow for sufficient flexibility to capture the 
complexities of the data, provided an appropriate number of knots for the spline is used[85]. 
Typically, the sensitivity of the results due to the knot figuration (i.e. the parametric shape of 
the baseline hazard) is assessed by re-fitting the model with a range of knot numbers and 
localization, and to compare the AIC (Akaike Information Criterium) and BIC (Bayesian 
Information Criterium). Such sensitivity analysis (figure 4.5) show only minimal differences 
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in the estimated number of life-years lost in study II, and the conclusions drawn are independent 




Figure 4.5: Temporal trends in loss in expectation of life (LEL) for male Diffuse Large B-cell 
Lymphoma (DLBCL) patients at ages 50, 60, 70 and 80 years at diagnosis estimated from 
different models with degrees-of-freedom (df) for the baseline hazard ranging from 4 to 6 and 






4.3.2.4 Survival in the presence of competing risks 
In this study we also estimated the probability of dying from lymphoma in the presence of 
competing risks, e.g., cardiovascular diseases, malignancy other than lymphoma, or other 
causes of death (Figure 4.6b). In terminology used for population-based cancer patient survival 
this measure is also known as the crude probability of death, as compared to the net probability 




Figure 4.6: Illustration of a) standard survival setting and b) competing risk setting 
 
As stated in section 4.3.1.5, net survival is useful for comparisons between groups when we 
want to eliminate death due to competing events. However, the somewhat awkward 
interpretation has limitations in the context of absolute risk estimation for patients. If we instead 
incorporate the competing risk of dying from other causes we can estimate crude survival. The 
interpretation of crude probability of death is: the probability of death in the real world where 
patients can die from other causes than cancer. This measure is useful in risk communication 
and treatment planning to understand the real-world probability of death. However, it is less 





4.3.3 Study III 
4.3.3.1 Allowing for repeated events 
Survival models are often used to study time to death but are not restricted to this outcome, we 
can use survival models for any type of event when also time to the event needs to be taken 
into account. When the outcome is death, it is only possible to have one event per study 
participant – we can only die once. After an individual has experienced the event then the 
individual is no longer at risk for the outcome i.e. is no longer contributing either any risk time 
or events to the analysis. In this study, the outcome of interest, acute myocardial infarction 
(AMI) can occur multiple times, and to capture this situation we incorporated repeated events 
into the model. 
Extensions to the Cox model have been developed to allow for repeated events[86] and we can 
implement similar models in the Flexible parametric model framework[87]. In general, 
repeated events in survival analysis are enabled by splitting the time-scale at event times so 
that we end up with several rows of data per individual that consist of non-overlapping follow-
up intervals (figure 4.7). These intervals ensure that individuals are at not at risk for their second 
event until after they have experienced their first event. 
 
 





The underlying shape of the baseline hazard is assumed to be the same for all events (first, 
second, third etc.) but we can relax this assumption by stratifying the survival model on event 
number. In a flexible parametric model this is done by fitting a time-dependent effect i.e. 
include an interaction between the baseline cumulative hazard and a covariate containing the 
interval number. However, including interval number in the models in this paper did not alter 
any conclusions (figure 4.8) and therefore we opted for a simpler model where the underlying 




Figure 4.8: Time-varying hazard ratio illustrating the relative risk of AMI among DLBCL 
patients compared to matched population comparators estimated from two different models, 
one where the shape of the baseline hazard is assumed to be the same for all events (pink) 
and one where event number has been included as a time-dependent effect (blue). 
 
4.3.4 Study IV 
4.3.4.1 Estimating real-world probabilities of patient trajectories using a Multi-state model 
approach 
Multi-state models can be used to quantify patient trajectories through different disease stages. 
We can think of the multistate model as a generalization of the competing risk model (Figure 
4.6b), where also intermediate states of interest can be added. A multistate model can be simple 
or complex, all depending on the number of states and the structure of the model e.g. if it is 
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possible to re-enter a state. States can be classified as “transient states” (that can be both entered 




Figure 4.9: Illustration of a multistate model with four states. All patients start in the state 
“Remission”. Each arrow between states is a transition and can be seen as a survival model. 
The state “Relapsed” is a transient state that can be both entered and exited and the two death 
states are absorbing i.e. once entered it is impossible to leave. 
 
The multistate models can be described as stochastic processes, {𝑌(𝑡), 𝑡 ≥ 0} taking values in 
a finite state space S. The transition probability, or the probability of being in a state b at time 
t, given that the process is in some state a at time s and the process history before s, can be 
defined as: 
𝑃(𝑌(𝑡) = 𝑏|𝑌(𝑠) = 𝑎, ℋ𝑠−) 
where (𝑎, 𝑏) ∈ 𝑆 and the history ℋ𝑠 = {𝑌(𝑢); 0 ≤ 𝑢 ≤ 𝑠} contains all previous observations 
of the process. 
4.3.4.2 The Markov model 
The expression of the transition probability can further be simplified by assuming that the 
probability of future transitions only depends on the current state and not the history leading 
up to it. This is known as the Markov property. The transition probability in a Markov model 
can be written as: 
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𝑃(𝑌(𝑡) = 𝑏|𝑌(𝑠) = 𝑎, ℋ𝑠−) = 𝑃(𝑌(𝑡) = 𝑏|𝑌(𝑠) = 𝑎) 
The transition intensity i.e. the hazard rate of going to one state to the next is now defined as: 
ℎ𝑎𝑏(𝑡) = lim
∆𝑡→0
𝑃(𝑌(𝑡 + ∆𝑡) = 𝑏|𝑌(𝑡) = 𝑎)
∆𝑡
 
The interpretation of the transition intensity is the instantaneous probability of going from state 
a to state b, given that you were in state a at time t. This is equivalent to the interpretation of 
the hazard rate of survival models in general. Essentially, a multi-state model can be specified 
by a combination of transition-specific survival models. 
The Markov assumption can be relaxed by allowing the probability of future transition to not 
only depend on the current state but to also depend on the time the current state was entered. 
𝑃(𝑌(𝑡) = 𝑏|𝑌(𝑠) = 𝑎, ℋ𝑠−) = 𝑃(𝑌(𝑡) = 𝑏|𝑌(𝑠) = 𝑎, 𝑇𝑎) 
where Ta is the time when state a was entered. This can be done in different ways, for example 
by including the enter time as a fixed covariate in the model, called the Semi Markov model. 
Another example is Markov renewal or clock-reset process. Time since entry in the current 
state, t-Ta, is then used as the underlying time scale. This is especially useful when the time 
since entry in the current state is of greater importance for the transition probability than the 
time since entry of starting state. This is often the case when the current state is more severe, 
such as recurrence of cancer for example. 
4.3.4.3 Estimating transition probabilities 
The fact that each transition can be viewed as a survival model makes the estimation of 
transition intensities straightforward. Predicting the transition probabilities is however more 
complicated. A variety of approaches has been suggested within a parametric framework; 
analytic calculations using maximum likelihood, numerical integration and ordinary 
differential equations[88-91]. In this study we used a simulation-based approach[92]. 
Simulation together with parametric transition models have the advantage of being less 
computer intensive and more generalizable especially when we want to include time-varying 
effect etc.    
We estimated transition intensities by fitting separate flexible parametric models for each 
transition. In this way, we are not restricted to the same distributional form for all transition 
models. Figure 4.10 show the model-based transition probabilities overlaid by the Aalen-






Figure 4.10: Comparison of the Aalen-Johanssen (non-parametric) estimates (A-J estimates) 
and the model-based estimates of the transition probability for the eight different disease-
stages included in the full multistate model in study IV. Note that the scale of the y-axis differs 






In summary, the main findings were: 
 
• The number of prevalent cases of NHL has increased between 2000 and 2016. The 
increase was seen in all three larger subgroups investigated: aggressive B-cell 
lymphoma, indolent B-cell lymphoma and T/NK-cell lymphoma and in all major 
morphological subtypes investigated. DLBCL, the most common subtype, was 
responsible for the largest increase in absolute number of prevalent cases. 
 
• The loss in life expectancy for patients diagnosed with DLBCL between 2000 and 2013 
has decreased overall, but a substantial number of life-years are still lost despite the 
addition of rituximab to the standard tretment, especially in high-risk patient groups. 
However, patients surviving the first two years after diagnosis have a favorable 
prognosis thereafter, with only minimal loss in life-expectancy compared to the general 
population regardless of age, sex or IPI-score. 
 
• DLCBL-patients receiving curative intent treatment have an increased risk of acute 
myocardial infarction compared to the general population. The excess risk was found 
to be highest immediately after diagnosis and to decrease to expected levels i.e. no 
excess risk around two years after diagnosis. The excess risk was driven by patients 
older than 70 years at diagnosis and with history of comorbidity. When restricting to 
DLBCL patients, advanced age, male sex and pre-existing comorbidity was associated 
with a higher risk of AMI but the investigated characteristics of the DLCBL were not. 
Patients and comparators with AMI had similar clinical presentation at the cardiac 
intensive care unit and similar 30-day survival.   
 
• More than 80% of all DLCBL patients achieving first line remission are alive and 
remain in remission after two years. An additional 2% are in second remission after 
relapse. The proportion of first-line remissions varied from 84% for the youngest 
patients (≤60 years) with aaIPI<2 to 50% for the oldest patients (>80 years) with 
aaIPI≥2. Patients with intermediate IPI-score (2-3) and with a high IPI-score (4-5) had 
12 and 24 percentage units lower probability of achieving this milestone, respectively, 
compared to patients with low IPI-score (0-1) when adjusting for age, sex and calendar 





5.1 STUDY I 
The number of prevalent NHL patients in Sweden increased between 2000 and 2016 as a result 
of both an increase in incidence and improved survival. In the beginning of the study period, 
2000-2007, the incidence of NHL remained virtually unchanged, but the incidence increased 
in the later years. On average, over the entire study period, the incidence increased by 1.3% 
annually (p<0.001). The increasing incidence trend was particularly pronounced among older 
males (aged >70 years, pinteraction=0.008). The relative survival of NHL overall improved 
continuously during the period (Figure 1). The two-year relative survival increased from 0.69 
(95%CI: 0.66-0.71) among patients diagnosed in 2000 to 0.82 (95%CI: 0.79-0.84) among those 
diagnosed in 2016. This corresponded to an annual decrease in NHL mortality of 3.6% 
(p<0.001). 
The increase of prevalent patients was observed in all clinical subgroups of NHL; aggressive 
B-cell lymphomas, indolent B-cell lymphomas and T/NK-cell lymphomas. The prevalence of 
almost all morphological subtypes increased during the study period. The only two subtypes 
with a decreasing trend in prevalence across the study period was small lymphocytic lymphoma 
(SLL) and aggressive B-cell lymphoma unspecified (ABCLU). The decreasing prevalence 
trends in these subtypes coincided with a decrease in incidence. 
The subtype responsible for the largest increase in the absolute number of patients was DLBCL. 
The number of prevalent patients diagnosed within the past 5 years increased by 66% from 
1,347 patients in 2004 to 2,236 patients in 2016. The incidence of DLBCL increased by 2.2% 
annually (p<0.001) and at the same time, the mortality rate decreased by 2.5% per year 
(p<0.001).  
The increase in incidence was seen especially among patients older than 70 years, the incidence 
increased on average by 2.6% per year compared to 1.7% among younger patients (≤70 years) 
(pinteraction=0.044). On the other hand, the excess mortality decreased primarily among younger 
patients (≤70 years), where the mortality rate decreased by 4.2% annually compared to 1.6% 
decrease among elderly patients (>70 years) (pinteraction<0.001). There were no interactions by 
sex, i.e. neither the trend in incidence nor that of excess mortality were different for males and 






Figure 5.1: Prevalence, incidence per 100,000 persons and 2-year relative survival 2000-
2016 for patients diagnosed with diffuse large B-cell lymphoma (DLBCL) by age-group. Left 
panel: age ≤ 70 years at diagnosis. Right panel: age > 70 years at diagnosis. 
 
5.2 STUDY II 
The life expectancy for patients diagnosed with DLBCL increased during the study period. 
However, there was still a significant loss in life expectancy, compared to the general 
population in all patient groups in 2013. For example, the life expectancy for a 70-year-old 
male patients increased from 6.5 years (95% CI 5.8-7.2) in 2000 to 10.1 years (95% CI 8.8-
11.4) in 2013, corresponding to an estimated loss in life expectancy of 7.6 years (95% CI 6.9-
8.3) and 4.8 years (95% CI 3.6-6.1), respectively. Expressed differently, the proportion of life 
lost was reduced from 54% (95% CI 49-59) to 32% (95% CI 24-41).  
Among patients alive two years after diagnosis, a clear increase in remaining life expectancy 
from two years post diagnosis and onwards was also noted over calendar time. Patients 
diagnosed in 2012 and who were alive two years after diagnosis lost two years or less compared 








Figure 5.2: Temporal trends in loss in life expectancy (LEL) for male Diffuse Large B-cell 
Lymphoma (DLBCL) patients with age adjusted International Prognostic Index (aaIPI) score 
≥2 at ages 40, 50, 60, 70 and 80 years at diagnosis. Estimates are shown for patients followed 
from diagnosis (left panel), and conditioned on 2-year survival (right panel) 
 
Lymphoma was the dominant cause of death in patients of all ages, sex and calendar year of 
diagnosis. However, the probability of lymphoma death was substantially reduced for 
patients who survived the first two years after diagnosis. It was primarily patients older than 
70 years at diagnosis who died due to other causes than lymphoma. Notably, a majority of 
elderly low risk patients (age >70 years at diagnosis, aaIPI<2) treated in the rituximab era, 








Figure 5.3: Probabilities of death due to lymphoma, cardiovascular disease (CVD), 
malignancy other than lymphoma, and other causes by age adjusted International 
Prognostic Index (aaIPI) score in Diffuse Large B-Cell Lymphoma (DLBCL) patients in 
Sweden older than 70 years at diagnosis and diagnosed 2007-2013. Estimates are shown 
for patients followed from diagnosis (left panel), and conditioned on 2-year survival (right 
panel) 
 
5.3 STUDY III 
Median age at diagnosis among patients treated curatively for DLBCL was 69 years and a 
majority of patients had pre-existing comorbidities. A total of 34.4% of patients had a history 
of severe comorbidities, sufficiently severe to motivate treatment alteration (e.g. reduced 
anthracycline dose) according to clinical experience. In addition, 22.1% of patients had only 
milder comorbidities (unlikely to motivate treatment alterations) e.g. hypertension. 
Patients treated curatively for DLBCL had an increased risk of AMI compared to the general 
population (HR: 1.33, 95% CI: 1.14-1.55). The excess rate was most pronounced shortly after 
lymphoma diagnosis and remained elevated for up to two years, but we found no long-term 
excess rate with up to 10 years of follow-up.  
When stratifying age at diagnosis (≤70/>70 years) and level of pre-existing comorbidity 
(none/mild/severe) we found that elderly DLBCL patients (>70 years at diagnosis), regardless 
of comorbidity level, and patients younger than 70 years with severe comorbidity had a 
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significantly higher AMI risk up to two years after diagnosis. Younger DLBCL patients (≤ 70 
years) without comorbidity had no excess rate of AMI within the observable follow-up. 
Risk factors for AMI after DLBCL diagnosis were older age, male sex and pre-existing 
comorbidities. For example, patients with only mild/moderate pre-existing comorbidity had a 
two-fold risk of AMI (HR: 2.11 95%CI 1.33-3.34) and patients with severe comorbidity had a 
three-fold risk of AMI (HR: 3.13 95% CI 2.01-4.85) compared to DLBCL patients without 
pre-existing comorbidities. However, characteristics of the DLBCL-diagnosis, such as stage, 
S-LDH level and performance status were not associated with risk for AMI.  
The AMIs occurring among DLBCL patients had similar characteristics (e.g. ECG rhythm, 
Killip class and infarction type etc) as the AMIs among the matched comparators. In addition, 
DLCBL patients received AMI treatment to the same extent as comparators and did have a 
similar 30-day survival after AMI. 
5.4 STUDY IV 
The prognosis for patients treated during the rituximab era and achieving remission after first-
line remission was generally favorable, with over 80 % of patients still alive and in remission 
after 2 years.  
Out of the 538 (18%) patients who experienced a relapse during follow-up, 72% relapsed 
within two years, and only 33 patients (6% of relapses, 1% of all patients) relapsed after more 
than five years. Among relapsing patients, 43% achieved a second remission although 51% of 
those also had a second relapse. 
Figure 5.4: The multistate model illustrating of the different stages that the patients may go 
through following remission after first line treatment. 
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The proportion of patients still in remission after two years varied by age and IPI-score, mainly 
reflecting the risk of early relapse among patients with higher IPI scores. At two years, a total 
of 8% (95% CI: 5-12) and 9% (95% CI: 7-12) of patients aged 61-70 and 71-80 years with 
aaIPI<2 had experienced a relapse compared to 17% (95% CI 12-21) and 22% (95% CI: 17-
26) of patients with aaIPI≥2.  
When controlling for age at diagnosis, sex and calendar year; clinical characteristics such as 
advanced stage (stage III-IV), poor performance status (ECOG ≥1), elevated S-LDH, more 
than one extranodal site and high IPI score (> 1) were all associated with lower probability of 
two-year remission. Patients with IPI 2-3 had a 12-percentage unit reduced probability of 
remaining in remission at two years and patients with IPI 4-5 had 24 percentage units reduced 





6.1 PUTTING THE RESULTS INTO CONTEXT 
We found a substantial increase in the number of prevalent patients in all clinical subgroups of 
NHL: aggressive B-cell lymphoma, indolent B-cell lymphoma and T/NK-cell lymphoma and 
in almost all major subtypes during the period 2000-2016. The prevalent patients are a mix of 
patients at different disease stages, living through and beyond treatment, including some with 
relapses and/or late effects of their cancer or treatment.  
Being the most common subtype, DLBCL was responsible for the largest increase in absolute 
numbers of prevalent patients which coincided with an increase in both incidence and survival. 
6.1.1 Improved survival  
The improved survival among DLBCL patients that we have demonstrated, aligns with the 
undisputed trend towards improved survival during the last decades. In fact, the 5-year relative 
survival has increased for NHL overall[20, 29], although the extent of the improvement has 
varied by sex, age group and lymphoma subtype[22]. DLBCL is one of the NHL subtypes that 
have seen the largest increase in 5-year relative survival[25, 29]. 
One explanation for the survival improvement is the addition of the anti-CD20 antibody 
rituximab to standard treatment. In combination with chemotherapy, rituximab has 
significantly improved both response rates and progression free survival in patients with B-cell 
malignancies[32, 93, 94]. However, rituximab was not stated as standard of care in the Swedish 
clinical guidelines until May 2006 (after which it was recommended to all patients regardless 
of stage and IPI). The life-expectancy among DLBCL-patients increased steadily even before 
that which could have been due in part to rituximab treatment within clinical trials prior to 
2006. Other possible explanations for improved survival during the 21st century include that 
larger fractions of elderly patients are considered eligible for more intensive treatment and that 
the supportive care during both primary and second-line treatments has improved. Today, novel 
drugs are also more widely recommended in the relapsed/refractory setting in national 
treatment guidelines. 
6.1.2 The results highlight patient groups in need of novel therapies 
Despite the survival improvements, the life-expectancy for patients diagnosed with DLBCL 
still remained substantially reduced compared to the general population, highlighting the needs 
of further improvements regarding treatment and care. Especially young high-risk patients still 
lost a considerable number of life-years due to the disease on average. For example, although 
halved between 2000 and 2013, the number of life-years lost for male patients age 50 years at 
diagnosis, with aaIPI≥2 was still 8.6 years in 2013 (17.5 years in 2000). 
Patients not eligible for curative intent treatment, who fail to complete planned treatment, who 
are refractory to treatment or patients that relapse represent the groups of patients where large 
challenges remain. Approximately 14% of all DLBCL in Sweden are not eligible for treatment 
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with curative intent and the median survival in this group of, mostly older, patients is only 2.9 
months [17]. Also, failure to complete planned R-CHOP treatment is associated with inferior 
survival[95]. Among patients treated with curative intent, 23% are either primary refractory of 
relapse within 5 years[17]. The survival after refractory/relapse is poor[36, 40, 45, 46, 49]. 
6.1.3 The importance of reporting prognosis conditioned on duration of 
follow-up  
On the other hand, by the end of the study period, the loss in life-expectancy for patients 
surviving the first two critical years after diagnosis was minimal, less than a couple of years, 
regardless of age, sex and even risk-group according to aaIPI. We speculate that this could be 
a consequence of a reduced and low risk of late relapses after this point. Similar results have 
been demonstrated in other populations, that patients that are event-free at two years after 
diagnosis have a life-expectancy similar to that of the general population[35, 36].  
The reassuring results for patients alive two years after diagnosis demonstrate the importance 
of reporting prognosis conditioned on duration of follow-up - both from a patient’s perspective 
and for health care planning reasons. As a consequence of the minimal loss in life-expectancy 
after two years from diagnosis, reported by us and others, the recommended follow-up of 
patients has been shortened from five to two years in several clinical guidelines[71, 73-75]. 
Naturally, the prognosis after a cancer diagnosis changes depending on if the patient is eligible 
for and tolerate curative treatment, the response to the treatment, and whether or not the cancer 
progresses or relapses. By using a multistate model approach, we were able to estimate real-
world probabilities of transitioning between different disease stages (first remission, relapse, 
second remission, second relapse, and death). In our study we demonstrate that the proportion 
remaining in first-line remission for at least two years (and hence reaching the two-year 
milestone discussed above) was over 80% for patients treated in the rituximab era and 
achieving remission following first-line therapy. The probability varied with age and IPI score, 
reflecting the different risks of early relapse and death while in remission from the DLBCL. 
The results also illustrate the difficulties in treating relapsing patients, second remissions were 
much less common and those remissions were less durable as half of the patients relapsed again.  
6.1.4 Patients have an increased risk of AMI  
The prevalent pool of patients is not only a mix of patients at different disease stages (and hence 
with different prognosis). The prevalent pool of patients is also representing patients with 
varying risk of physical and psychological late effects of their cancer diagnosis and treatment.  
We found that there was an increased risk of AMI among curatively treated DLBCL-patients 
compared to the general population. However, the excess risk varied over follow-up time and 
was most pronounced early after diagnosis and subsequently diminished after two years. With 
a maximum of 10 years of follow-up, there was no indication of long-term risk. Advanced age, 
male sex and comorbidity were associated with an increased rate of AMI among DLBCL-
patient. In patients older than 70 years at diagnosis the excess risk of AMI was seen even for 
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patients with only milder comorbidity such as hypertension or diabetes while among younger 
patients, an excess risk was only associated with severe pre-existing comorbidity. 
In line with our results, a study based on SEER-Medicare data, found an increased rate of AMI, 
most pronounced during the first 6 months after DLBCL-diagnosis among older patients (>65 
years) compared to cancer-free controls[63].  
There can be several explanations to why DLCBL patients have an increased risk of AMI, 
where the treatment is one of them. In a Swedish study from 2012, most cancer sites, including 
NHL, are associated with an initial higher risk of CVD diseases according[96]. In a SEER-data 
study, several cancer sites, again including NHL, were associated with an initial increased risk 
of myocardial infarction and stroke[97]. The increased risk may of course have different 
underlying causes for different cancer sites. Possible causes are common risk factors, cancer 
related inflammation and hemostatic activation, stress related to receiving a cancer diagnosis 
or side effects of treatment[96, 97]. 
The standard chemotherapy regimen administered to DLBCL patients contains the 
anthracycline doxorubicin with cardiotoxic effects that have been known for decades[61]. 
Doxorubicin is considered the most important drug when aiming for cure of DLCBL and 
therefore also elderly patients and patients with relatively severe comorbidity are often 
considered for treatment. There is a lack of specific guidelines on how to treat DLBCL patients 
with risk of cardiovascular disease, but the field is rapidly growing with initiatives such as large 
cardio-oncology units and also guidelines for assessment and monitoring risk [98, 99]. 
6.2 STRENGTHS AND LIMITATIONS 
A strength of the studies in this thesis is the use of data from the SLR. Compared to the National 
Cancer Register to which reporting is mandatory by law, the coverage is around 95%[64]. The 
high coverage of SLR provides a truly population-based cohort and in addition the SLR allow 
us to identify lymphoma subtypes.  
SLR was launched in year 2000 and over the years, there have been changes in registration 
practice and accuracy of subtype classification. The morphological coding of subtypes has 
successively been revised as diagnostic techniques have improved, leading to new definitions 
of subtypes. A limitation is that it was not possible to fully distinguish between more detailed 
subtypes of DLBCL (e.g. primary mediastinal B-cell lymphoma, T-cell rich DLBCL and ALK-
positive DLBCL) already from the year 2000. Another consequence, that could possibly affect 
subtype specific trends in incidence and survival, is that the number of unspecified lymphoma 
diagnoses has decreased which leads to larger underestimation of subtype-specific measures 
early in the study period. 
The SLR contains detailed information about patient characteristics which enabled us to study 
risk-groups based on IPI. Although IPI was developed back in the 1990s it has been shown to 
be a robust prognostic score even in the rituximab era and is still used in clinical practice. A 
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common critique against IPI is that it is too simplistic and could lead to loss of predictive 
accuracy[100].  
Unfortunately, the SLR does not include more recent prognostic markers such as cell of origin 
or double-/triple-hit lymphoma (MYC/BCL-2/BCL-6 translocations). Cell-of origin strongly 
predict the outcome, where patients with ABC-DLBCL have a less favorable outcome[4, 101, 
102]. Still, additional genetic complexity remains to be defined to provide insights into disease 
pathogenesis, identify candidate treatment targets, tailor treatment and better predict 
outcome[101, 103-107]. 
Progressively more information has been included in SLR since the start. Data on primary 
treatment and response to primary treatment have been registered in SLR since 2007 and 
relapse information is collected since 2010. However, SLR lack information for example 
regarding anthracycline dose reductions which was a limitation when studying risk of AMI in 
patients treated for DLBCL in Study III.  
During 2017-2019 we performed a national update of the SLR to ensure the completeness of 
primary treatment and relapse information for patients diagnosed with DLBCL between 2007 
and 2014. The chart review together with the extensive data collection on refractory/relapsing 
patients has generated access to unique, high quality and rich data. Unfortunately, at the time 
when the second study in this thesis was performed, this information was not yet available 
which prevented us from studying event-free survival and test the hypothesis of a trend towards 
reduced risk of later relapses. Another limitation was that thus far, the collected data on later 
relapses/later line treatments has not been linked to other Swedish health registers, such as the 
National Patient Register or the Prescribed Drug Register.  
Another strength is the use of novel statistical methodology to provide clinical useful and easy-
to-interpret measures of disease burden. Population-based cancer survival is often reported 
using cause-specific survival or relative survival[69]. Although these are valid and useful 
measures for comparisons between groups (when we want to eliminate any differences in 
background mortality) it is less useful for risk communication purposes and in health care 
planning[76].  
In contrast to summarizing survival at e.g. five years after diagnosis, loss in life expectancy 
summarizes the prognosis over the entire life-span to fully capture the impact of treatment 
regimens and patient management on survival. However, estimating loss in life expectancy 
requires extrapolation of survival beyond the range of available data. The extrapolated rates 
should be interpreted with care, especially in young patients, as the models assume that no 





The number of prevalent patients has increased for almost all major subtypes of NHL during 
the 21st century. DLBCL, being the most common subtype is responsible for the largest 
increase in absolute numbers. 
The prognosis for patients diagnosed with DLBCL has improved during the past decades and 
more and more patients are living through and beyond their diagnosis and treatment. In 
particular, patients surviving the first two years have a favorable prognosis. However, despite 
improvements following the introduction of rituximab, the results highlight continued large 
losses of life among young high-risk patients, driven by primary refractory disease and early 
relapse in some patients.  
The general improvement in the outcome for DLBCL patients in combination with an aging 
population will increase the need for adequate cardiology monitoring. The excess risk of AMI 
among primarily older patients and within the first two years of diagnosis and treatment should 
be a signal to the treating hematologist/oncologist that cardiac monitoring is of importance, 
even for patients with milder comorbidities.  
However, given the poor prognosis for patients when treatment fails, it does not seem 
appropriate to withhold doxorubicin from all of the comorbid older patients as the absolute risk 
of a cardiovascular event is still low. Primary refractory disease and early relapses remain the 




8 POINTS OF PERSPECTIVE 
Patients refractory to first-line immunochemotherapy or with early relapse remain the main 
challenge in DLBCL patient care. The treatment options when initial therapy fails are limited, 
especially among elderly patients (>70 years) and population-based studies show that more 
than half of the refractory/relapsing patients only received palliative treatment or no treatment 
at relapse[44, 108]. 
Patients 70 years or younger with refractory disease or relapse are recommended second-line 
chemotherapy and consolidation with ASCT aiming for cure. However, remission on second-
line therapy cannot always be obtained and relapses following ASCT are common. Therefore, 
new therapeutic strategies are needed for relapsed/refractory patients in all age groups. A range 
of novel therapies are currently undergoing evaluation in clinical trials or have recently been 
approved in relapsed/refractory DLBCL. One of the most important is the chimeric antigen 
receptor t-cell therapy (CAR T) that has demonstrated promising results in phase II-studies in 
relapsed/refractory DLBCL patients[109, 110]. Currently two CAR T-cell therapies are 
approved by FDA and EMA but several other are undergoing clinical trials. Another promising 
group of agents are the bispecific antibody therapies. 
CAR T-cell therapy is still at the beginning of its development and much work remains to 
reduce manufacturing times, lower toxicity and make it tolerable for broader patient groups. 
To this point, only a few DLBCL-patients have been treated in Sweden with CAR T-cell 
therapy. A preliminary evaluation of the eligibility of CAR T-cell therapy in a population-based 
setting (based on the data collection on refractory/relapsed DLBCL-patients described in 
section 4.1.2) indicate that only about 17% of first-relapse and even fewer second-relapse 
patients would be eligible for CAR T-cell therapy with today’s eligibility criteria from ongoing 
clinical trials[111]. However, given the poor prognosis with standard treatment options, the 
hope is that these new drugs will bring new possibilities for cure and also that they eventually 
will be tolerated among broader patient groups. 
A majority of new drugs are designed based on the increasing understanding of genetic 
differences of DLBCL. As opposed to the current standard of care, i.e., R-CHOP treatment and 
a “one size fits all” approach, the aim of personalized medicine is to optimize the choice of 
treatment for each individual patient based on their genetic tumor profile and thus sparing them 
the unnecessary toxicity of a drug less likely to work for them. Another aspect is that some of 
the more targeted therapies are associated with high costs, therefore it is even more important 
that they are administered to patients who will actually benefit from them.  
Population-based statistics play an important role to identify patient groups in need of modified 
or alternative treatments, and to evaluate long-term effects and efficacy of new therapies/drugs 
in the “real-world” after drug approval. Although randomized clinical trials (RCT) are gold 
standard for evaluating the effect of new treatments, they are often limited to small sample 
sizes, short follow-up and highly selected patient groups. All factors that may limit the 
generalizability into the clinical reality. 
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The number of prevalent NHL patients has increased in Sweden since the beginning of the 21st 
century and will likely continue to do so due to improved survival. This means that more and 
more patients are living beyond their diagnosis which raises questions about how these patients 
should best be cared for in the long run. When the outcome of the cancer improves, more and 
more focus shifts towards survivorship issues e.g. quality of life, fertility, physical or 
psychological late-effects etc. AMI, as studied in one of the papers in this thesis, is only one of 
many health conditions that DLBCL-patients are at increased risk of as a consequence of their 
cancer (either the cancer itself or its treatment).  
Population-based quality registers, such as SLR are a gold mine for research as it enables long 
follow-up of all patients, including patients who may not be represented in clinical trials, e.g. 
older patients or patients with comorbidity. In addition, the data collection that we performed 
on refractory/relapsing DLBCL patients (described in section 4.1.2) has provided detailed 
clinical information on a group of patients that is difficult to treat today. When used in 
combination with the SLR it is therefore a valuable source of increased knowledge about this 
vulnerable patient group. 
Lastly, a rather new concept in population-based research is register-based randomized clinical 
trials (R-RCT), a field in which the Swedish quality register SWEDEHEART is world-leading 
today. The idea is that patients can be recruited, randomized and followed within the 
infrastructure of the registry. Advantages, besides it being cost-effective, is that it enables 
recruitment of large numbers of unselected patients and thereby a better reflection of the 
clinical reality[112]. R-RCTs should be seen as a complement to standard RCT and is 
particularly useful when comparing treatments already in use in clinical practice. Examples of 
potential applications related to the studies in this thesis could be to use R-RCTs to evaluate 
the real-world efficacy of newly approved drugs, evaluate prophylactic treatments/routines to 
reduce cardiovascular diseases among patients or evaluate alternative follow-up schemes of the 
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